Plant-Based Biomanufacturing Platforms Advance

- Plant-based production of biologics can be significantly more cost-effective than traditional methods, estimated to be 2-10% of the cost of microbial fermentation and just 0.1% of the cost of mammalian cell culture systems. Transient expression systems, which do not require stable genomic integration, can yield detectable recombinant proteins in as little as 3-7 days, dramatically shortening development timelines compared to the weeks or months required for stable mammalian cell line development. - For viral vector manufacturing, a critical area for gene therapy, companies like Généthon and Samabriva are partnering to develop AAV production processes in plants. This approach aims to overcome the significant cost and scalability limitations of current AAV manufacturing methods, which often struggle to produce sufficient quantities for high-dose therapies or prevalent diseases. - The regulatory pathway for plant-made pharmaceuticals (PMPs) involves both the USDA, which focuses on the environmental containment of the genetically modified plants, and the FDA, which regulates them as biologic drugs. While no GE pharmaceutical plant has been granted non-regulated status, requiring permitted and contained growth, the first PMP approved for human use was Elelyso, an enzyme produced in carrot cells, approved by the FDA in 2012. - Automation and digital technologies are being integrated into plant-based manufacturing to enhance efficiency and reproducibility. This includes the use of robotics and computer vision for precise handling of plant tissues, automated control of growth environments, and data management systems like LIMS for traceability throughout the production process. - AI and machine learning are being applied to optimize plant bioprocesses, from predictive modeling of protein expression to refining downstream purification. Digital twins—virtual replicas of the physical manufacturing process—are being developed to simulate and predict outcomes, enabling process optimization and real-time monitoring without extensive physical experimentation. - From a quality and biochemical standpoint, plant-based systems can offer advantages in post-translational modifications, such as producing more homogenous N-linked glycosylation patterns on proteins compared to the heterogeneity often seen in CHO cells. This consistency is critical for the efficacy and stability of therapeutic proteins. - Key players in the plant-based biologics space include companies like Medicago, Kentucky BioProcessing, and Protalix BioTherapeutics, which developed the first FDA-approved plant-made drug. The market is driven by these innovators and collaborations between biotech firms and academic institutions to commercialize new products.